1. Home
  2. EH vs REPL Comparison

EH vs REPL Comparison

Compare EH & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EHang Holdings Limited ADS

EH

EHang Holdings Limited ADS

HOLD

Current Price

$9.88

Market Cap

745.8M

Sector

Industrials

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$2.61

Market Cap

692.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EH
REPL
Founded
2014
2015
Country
China
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
745.8M
692.8M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
EH
REPL
Price
$9.88
$2.61
Analyst Decision
Strong Buy
Hold
Analyst Count
3
9
Target Price
$22.47
$5.67
AVG Volume (30 Days)
505.1K
9.7M
Earning Date
05-26-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.25
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$33.23
N/A
Revenue Next Year
$73.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.06
$1.50
52 Week High
$20.44
$13.24

Technical Indicators

Market Signals
Indicator
EH
REPL
Relative Strength Index (RSI) 38.27 34.76
Support Level $9.06 $1.50
Resistance Level $11.94 $6.17
Average True Range (ATR) 0.41 0.53
MACD -0.09 0.01
Stochastic Oscillator 4.41 22.07

Price Performance

Historical Comparison
EH
REPL

About EH EHang Holdings Limited ADS

EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: